8 results about "Telangiectasia" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The present application relates to a drug or pharmaceutical composition for preventing, alleviating, or treating cancer and a use thereof, as well as a method for preventing, alleviating, or treating cancer. The drug or pharmaceutical composition of the present application is capable of interfering with ataxia-telangiectasia mutated and Rad3-related kinase (ATR) and mammalian target of rapamycin (mTOR) activity, causing inactivation or reduced activity of ATR and mTOR. The present application provides a novel dual-target strategy for the treatment of cancer.

The invention relates to a small transcranial magnetic stimulation positioning device and method based on remote control, and the device comprises a helmet, a control host, and a medical control host. A detection space is arranged in the helmet, a camera module and a three-axis moving module are arranged in the detection space, and a positioning unit and an angle adjusting module are arranged at the movable end of the three-axis moving module; the positioning unit comprises a mounting plate, guide sleeves are vertically arranged at four corners of the lower surface of the mounting plate, guide columns are slidably arranged on the guide sleeves in a penetrating manner, and a treatment coil is arranged on the lower surface of the mounting plate; the cost can be greatly reduced, and meanwhile, the method can be well implemented; the four pressure sensors not only can detect the head shape, but also can be directly associated with the treatment coil in hardware, the position of the treatment coil can be accurately and directly obtained, and meanwhile angle adjustment and height adjustment of the treatment coil can be conducted according to needs. By means of the device, continuous treatment of the erythema rosacea can be conveniently conducted on a patient at home.

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

The application discloses a kit for constructing an ATM gene mutation ataxia-telangiectasia model pig nuclear transfer donor cell. The application provides a kit comprising ATM-gRNA1 shown in SEQ ID NO: 16, ATM-gRNA4 shown in SEQ ID NO: 17 and NCN protein. The application also provides a method for preparing a recombinant cell: co-transfecting a pig cell with ATM-gRNA1, ATM-gRNA4 and NCN protein to obtain a recombinant cell. The recombinant cell is a recombinant cell with ATM gene mutation. The kit is used for: preparing a recombinant cell; preparing an ataxia-telangiectasia model pig; preparing an ataxia-telangiectasia cell model or an ataxia-telangiectasia tissue model or an ataxia-telangiectasia organ model. The application has great application value for research and development of ataxia-telangiectasia drugs and revealing the pathogenesis of the disease.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for treating rosacea, its preparation method, and its application. This invention provides a traditional Chinese medicine composition for treating rosacea, comprising dandelion, purslane, sophora flavescens, sophora japonica flower, and rhubarb. The traditional Chinese medicine composition of this invention has the effects of clearing heat and detoxifying, reducing inflammation and antibacterial properties, cooling blood and promoting blood circulation, and repairing the skin barrier. It can be used to treat erythematous rosacea, relieving erythema, telangiectasia, papules, itching, and burning sensation on the skin, and reducing the risk of recurrence.

The disclosure relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of an PLG gene and methods of treating subjects having an PLG-associated disease or disorder, such as hereditary hemorrhagic telangiectasia (HHT), using such dsRNA agents and compositions.